CV Therapeutics Pulls Ranexa Marketing Application In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm says it plans to resubmit the application for the chronic angina therapy upon completing “one or several” pharmacokinetic studies.
You may also be interested in...
CV Therapeutics Readies Ranexa For Launch In March
Pending its approval, ranolazine will be supported by 250 sales reps detailing to top prescribing cardiologists.
CV Therapeutics Readies Ranexa For Launch In March
Pending its approval, ranolazine will be supported by 250 sales reps detailing to top prescribing cardiologists.
Ranexa NDA Amendment Seeks Restricted Angina Indication
CV Therapeutics' complete response to FDA's October 2003 "approvable" letter is based on the ERICA trial in patients refractory to the maximum labeled dose of Pfizer's calcium channel blocker Norvasc.